title: Prognostic role of cytovillin expression in patients with osteosarcoma: a meta-analysis.
abstract: Cytovillin plays structural and regulatory roles in the assembly and stabilization of specialized plasma membrane domains and in the tumor angiogenesis. Cytovillin expression has been proposed to be an effective biomarker of prognosis in patients with osteosarcoma, and many studies have been performed to assess the prognostic role of cytovillin expression in patients with osteosarcoma. We performed this meta-analysis to provide a comprehensive evaluation of the role of cytovillin expression on the overall survival rate by calculating the pooled risk ratio (RR) with corresponding 95% confidence interval (95% CI). Finally, eight studies with a total of 415 patients with osteosarcoma were included into the meta-analysis. Meta-analysis of total eight studies showed that cytovillin expression was obviously associated with lower overall survival rate in patients with osteosarcoma (RR = 0.41, 95% CI 0.28–0.58, P < 0.001). Meta-analysis of five studies with large sample still showed that cytovillin expression was obviously associated with lower overall survival rate (RR = 0.48, 95% CI 0.38–0.60, P < 0.001). In conclusion, the meta-analysis shows that cytovillin expression is obviously associated with lower overall survival rate in patients with osteosarcoma, and it is an effective biomarker of prognosis.
authors: Shibing
authors: S
authors: Guo
authors: Rui
authors: R
authors: Bai
authors: Wei
authors: W
authors: Zhao
authors: Yuxin
authors: Y
authors: Wang
authors: Zhenqun
authors: Z
authors: Zhao
authors: Wei
authors: W
authors: Feng
mesh_terms: D001859:Bone Neoplasms / Q000235:genetics* / Q000401:mortality*; D003598:Cytoskeletal Proteins / Q000235:genetics*; D006801:Humans; D012516:Osteosarcoma / Q000235:genetics* / Q000401:mortality*; D011379:Prognosis; D012306:Risk; D000099149:Ezrin
chemical_list: D003598:Cytoskeletal Proteins; D000099149:Ezrin
references: Ann Oncol. 2010 Oct;21 Suppl 7:vii320-5
references: 20943636
references: J Bone Joint Surg Br. 2012 Mar;94(3):419-24
references: 22371553
references: Curr Opin Cell Biol. 2011 Aug;23(4):377-82
references: 21592758
references: Virchows Arch. 2007 Dec;451(6):999-1007
references: 17786474
references: J Cell Biochem. 1988 Sep;38(1):65-75
references: 3065344
references: Cancer. 2006 Aug 1;107(3):554-62
references: 16795069
references: Ortop Traumatol Rehabil. 2011 Nov-Dec;13(6):537-45
references: 22248458
references: Mod Pathol. 2010 Jul;23(7):1012-20
references: 20348881
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: J Cell Sci. 1997 Dec;110 ( Pt 24):3011-8
references: 9365271
references: Tumori. 2009 Jan-Feb;95(1):81-6
references: 19366061
references: J Comp Pathol. 2012 Feb-Apr;146(2-3):132-42
references: 22297074
references: Int J Cancer. 2009 Nov 15;125(10):2239-45
references: 19588507
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120
references: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references: 13655060
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: J Pediatr Hematol Oncol. 2010 Aug;32(6):e213-7
references: 20562647
references: Virchows Arch. 2010 Jul;457(1):87-9
references: 20552365
references: J Biol Chem. 1989 Oct 5;264(28):16727-32
references: 2674140
references: Med Oncol. 2011 Dec;28 Suppl 1:S636-43
references: 20859706
references: Clin Orthop Relat Res. 2007 Jun;459:229-36
references: 17353802
references: Clin Invest Med. 2009 Apr 01;32(2):E180-8
references: 19331807
references: Cancer Res Treat. 2009 Sep;41(3):138-44
references: 19809563